Placeholder Banner

Post-election Scenarios to Microbiome Therapies—Diverse Panels at 2016 BIO Investor Forum

October 6, 2016
Government policy and regulation, investment trends, latest discoveries, drug development, licensing and other topics will be covered during panel sessions at the 15th annual BIO Investor Forum Oct 18-19 in San Francisco.

Among the varied educational topics covered during the conference is one that can only occur every four years: the presidential election. The presidential campaign is generating interest from all sectors of American society—and rightfully so. The decision made in November will impact all of us, certainly for the next four years and perhaps for many years to come. Healthcare policy and drug valuation discussions have percolated through the campaign season and the attention correlates with a slowdown in stock market returns to biotech.  As Election Day approaches, the question remains, how will the biotech sector be affected by a new president’s healthcare agenda? A panel of experts will weigh these suppositions against a backdrop of a healthy global licensing and merger and acquisition market as well as other deal activity in the sector.

The session will be held on day two of the conference which is being held Oct 18-19 at the Westin St. Francis in San Francisco.

Speakers include:

  • John Chambers, Vice-Chairman and Head of Healthcare Investment Banking, ROTH Capital Partners

  • Asthika Goonewardene, Senior Analyst, Bloomberg Intelligence

  • Brian Hagerty, Senior Director, New York Stock Exchange (NYSE)

  • Allison Kean, MD, Senior Director for Cardiovascular and Women’s Health, Pfizer

  • Brian Leuthner, Co-Founder, President and Chief Executive Officer, Edge Therapeutics, Inc.


While the presidential election panel will build scenarios based on the outcome of human behavior, another panel will tackle the non-human microbiome. Recent years have seen a lot of excitement in the microbiome space and there is hope of bringing new microbiome-derived drugs and therapies to the market.  As more collaborations get underway and investment grows, including the $121M National Microbiome Initiative commitment from the White House, we can anticipate that this space will garner more attention as biopharma develops new approaches and advances candidates further into the clinic.  However, getting microbiome-inspired candidates to become commercially viable therapeutics presents a number of challenges, including uncertainties in drug development and questions about intellectual property and regulatory pathways. This panel will feature discussions about current experiences in microbiome drug development and the promising future of microbiome therapies.

Moderator Andres Hurtado-Lorenzo, PhD, Director of Translational Research, Crohn’s and Colitis Foundation of America, will be joined by:

  • Colleen Cutcliffe, PhD, Co-founder and Chief Executive Officer, Whole Biome

  • Glenn Nedwin, PhD, MoT, Chief Executive Officer and President, Second Genome, Inc.

  • Heather A. Wasserman, PhD, Senior Director, Eli Lilly and Company


It’s not too late to register to attend!

If you are a qualified reporter working full time for print, broadcast or a web publication with valid press credentials, your registration is complimentary.